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Abstract
Osteoporosis in patients with broncho-pulmonary pathology is associated with the fact that the inflammatory
process has a direct effect on bone metabolism. A large number of pro-inflammatory cytokines, which play
an important role in the pathogenesis of obstructive pulmonary diseases, is involved in the regulation of bone
resorption. In addition, patients with chronic obstructive pulmonary disease (COPD) of severe and extremely
severe degrees, according to GOLD recommendations, receive inhaled glucocorticosteroids (GCS), and in
ineffective inhaled GCS-therapy COPD patients are prescribed systemic steroids; that has an undesirable effect
on bone marrow state.
The purpose of the work was to investigate the peculiarities of bone metabolism disorders in patients with COPD.
There were examined 26 patients with COPD of the III-IV degrees, groups C and D aged 65.3±3.15 years.
Spirography, bone mineral density study were performed; ten-year risk of osteoporotic fractures was evaluated
using FRAX; content of calcium, phosphorus, alkaline phosphatase in blood serum were determined.
As a result of laboratory studies and densitometry, 84.6% of patients were diagnosed osteopenia. The average
T-criterion was within (-1.83±0.17) SD (standard deviation) and was significantly lower than in healthy persons
(-0.56±0.10) SD, (p<0.001). The degree of reduction of bone mineral density depended on the degree of
reduction of FEV1 and COPD degree (r=0.65; p<0.01), as well as on the duration of the disease (r=-0.43;
p<0.01). The ten-year risk of osteoporotic fractures in patients with COPD was high and was 5.65%±1.63%, as
opposed to 2.13%±0.61% (p<0.001) in practically healthy individuals.
Thus, severe functional disorders in COPD, a durable anamnesis of the disease contribute to a decrease in bone
mineral density and to an increase in the risk of osteoporotic fractures.
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Problem statement and analysis of
the latest research
Osteoporosis is a systemic disease of the skeleton,
which is characterized by a decrease of bone mass, a
violation of the micro-architectonics of bone tissue,
which leads to the increased bone fragility and the
risk of fractures [1].
Among the risk factors for osteoporosis the un-
modified (genetic), modified factors, and medica-
tion influence can be identified. On the one hand,
the role of hereditary predisposition to this disease
is incontrovertible; on the other hand – the value of
such ”exogenous” risk factors as deficiency of pro-
tein, calcium, vitamin D, smoking, alcohol abuse,
hypodynamia, low body mass, early menopause
in women is firmly proven. [7, 10]. Among the
diseases that contribute to the development of os-
teoporosis, a special place belongs to the chronic
obstructive pulmonary disease (COPD). This is due
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to the commonality of many exogenous risk factors
for the development of osteoporosis and COPD,
mechanisms of pathogenesis, and the influence of
medicines used in the treatment of COPD [2, 4].
Osteoporosis in patients with broncho-pulmonary
pathology belongs to the category of secondary
ones. It is associated with the fact that the in-
flammatory process has a direct effect on bone
metabolism. A large number of pro-inflammatory
cytokines, playing an important role in the patho-
genesis of obstructive pulmonary disease, is in-
volved in the regulation of bone resorption. Tumor
necrosis factor-α contributes to the increase of num-
ber and maturation of osteoblasts [8]. Interleukin-1
(IL-1) and interleukin-6 (IL-6) are powerful medi-
ators of osteoclastogenesis (according to in vitro,
IL-1 is a 4-fold stronger factor in bone resorption
than parathyroid hormone). Thus, the effect of these
and other cytokines, including IL-11 and monocyte-
macrophage colony-stimulating factor, is explained
by the relationship between the inflammatory pro-
cess in the broncho-pulmonary system, bone remod-
eling, and loss of bone mass [2, 10].
In addition, patients with COPD of severe and
extremely severe degrees, according to GOLD rec-
ommendations, receive inhaled glucocorticosteroids
(GCS) as the part of basic therapy. The proven sys-
temic effects, developing in response to the use of
high doses of inhaled GCS (over 1000 micrograms
per day for beclomethasone dipropionate and over
750 micrograms per day for fluticasone), include os-
teoporosis in adults and the effect on linear growth
in children [3, 5, 9].
When glucocorticoid therapy is ineffective, pa-
tients with COPD are sometimes prescribed sys-
temic GCS; it also has an undesirable effect on bone
tissue metabolism. Meta-analysis of the results of
controlled studies has shown that the appointment
of even minimal (2.5 mg/day) doses of GCS may
have an adverse effect on bone state. The highest
loss of bone tissue develops during the first 6-12
months of GCS-therapy [2]. The main peculiar-
ity of steroid osteoporosis – is the effect of GCS
on both processes underlying remodeling of bone
tissue: decrease of osteoblast-mediated formation
and increase of osteoclast-mediated bone resorption.
Additional factors in this process are the reduction
of the synthesis of collagen and non-collagen pro-
teins, as well as local factors of bone tissue growth
(insulin-like growth factor-1, transforming growth
factor, etc.) [4, 6].
It should be emphasized that osteoporosis in
patients with COPD also develops in the absence
of GCS-therapy. Among patients with COPD with
FEV1 below 80% of the appropriate, who have
never received GCS, osteoporosis (according to T-
criterion) was registered 4 times more than in the
control group. Vertebral fractures were observed in
12.4% of patients with COPD with moderate func-
tional impairment (FEV1 is 70% of appropriate),
who did not receive GCS [6, 7].
Objective: to investigate the peculiarities of
bone metabolism disorders in patients with chronic
obstructive pulmonary disease.
1. Materials and Methods
There were examined 26 patients with COPD of the
III-IV degree, groups C and D and 12 practically
healthy persons. The average age of patients was
65.3±3.15 years. Among the examined patients, 18
(69.2%) men had COPD of the III degree; 8 (30.8%)
– had COPD of the IV degree. In 14 (53.8%) pa-
tients group C was determined, and in 12 (46.2%)
– group D of this disease. To confirm the diagno-
sis of COPD, patients were performed a clinical,
laboratory and instrumental examination in accor-
dance with the Order of the Ministry of Health of
Ukraine #555 dated June 27, 2013; and according to
International Recommendations GOLD-2017. The
treatment schemes included inhaled GCS as basal
medicines, and 12 (46.2%) patients received sys-
temic GCS [1, 5]. Investigation of bone mineral
density (BMD) was performed using an X-ray den-
sitometer ”CHALLENGER” with an evaluation of
the results according to the T-criterion in standard
deviations (SD) from bone mass. The ten-year risk
of osteoporotic fractures was calculated using the
FRAX computer program. The content of calcium,
phosphorus, alkaline phosphatase in blood serum
was studied. Patients provided informed consent to
participate in the clinical trial. Statistical processing
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of indicators was carried out using the application
package of computer programs Statistica 7.
2. Results and Discussion
Figure 1. Laboratory indices of calcium metabolism in the examined patients.
In the course of the
study, it was found
that most patients with
COPD complained of
coughing with puru-
lent sputum discharge,
shortness of breath. 21
(80.8%) patients in the
anamnesis pointed to
smoking, and 4 pa-
tients (15.4%) – for
the presence of data on
the impact of occupa-
tional hazards. The
majority of patients
had classic objective
signs of COPD, 18 pa-
tients (69.2%) were di-
agnosed signs of de-
compensated pulmonary
heart. Spirographic parameters corresponded to
the broncho-obstruction degree and the degree of
COPD. Laboratory indices of exchange of calcium
and phosphorus did not differ significantly from
indicators in healthy individuals (see Fig. 1).
Results of densitometry of the lumbar spine L2-
L4 are represented in Fig. 2. The average indicators
of the T-criterion were within (-1.83±0.17) SD and
were significantly lower than in healthy persons
(-0.56±0.10) SD (p<0.001). As it is known, in
COPD the treatment with GCS has a negative in-
fluence not only on ”quantity” (mineral density of
bone tissue), but also on ”quality” of bone. This
leads to the fact that the ”threshold of fracture” in
patients receiving GCS is lower than in those who
do not take these medicines. That is why in most
cases, steroid osteoporosis is diagnosed according
to the T-criterion of osteo-densitometry not at 2.5,
but at 1.5 standard deviations (SD) from the peak
bone mass of persons of the corresponding gender
[2]. The peculiarity of steroid osteoporosis is a
more pronounced lesion of the trabecular (spine,
trochanter major) than of the cortical (long bones)
bone tissue [6].
Osteopenia was diagnosed in 22 (84.6%) pa-
tients. The degree of reduction in mineral density
of bone tissue depended on the degree of reduction
of FEV1 and the degree of COPD (r=0.65; p<0.01).
Figure 2. Results of densitometry in the
examined patients. Note: Statistical significance of
differences from healthy persons * p<0.001
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The inverse correlation relationship was found
between the index of bone mineral density and the
duration of the disease (r=-0.43; p<0.01).
The ten-year risk of osteoporotic fractures in pa-
tients with COPD was high and was 5.65%±1.63%,
as opposed to 2.13%±0.61% (p<0.001) in practi-
cally healthy individuals. As it is known, the rel-
ative risk of fractures of the skeletal bones (spine,
femoral bone) increases with the dose-dependent
GCS [6, 9].
3. Conclusions
1. Based on the performed studies, it was found
that more than 80% of patients with COPD
of the III-IV degree, groups C and D have
osteopenia.
2. Severe functional disorders in COPD, a durable
anamnesis of this disease contribute to a de-
crease in mineral density of bone tissue and
an increase of the risk of osteoporotic frac-
tures.
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